CN Patent

CN117427076B — 来那替尼在制备预防或治疗动脉粥样硬化药物中的应用

Assigned to Anhui Provincial Hospital First Affiliated Hospital Of Ustc · Expires 2025-09-19 · 1y expired

What this patent protects

本发明公开了一种来那替尼或其药学上可接受的盐或水合物在制备预防或治疗动脉粥样硬化性疾病的药物中的应用。动脉粥样硬化性疾病是一种血管内壁慢性炎症性疾病。低密度脂蛋白和炎症性细胞持续在血管内壁受损部位累积，逐渐形成脂质条纹，进一步发展为脂质斑块，即动脉粥样硬化。来那替尼具有抑制炎症反应的效果，从而用于制备预防或治疗动脉粥样硬化性疾病的药物。

USPTO Abstract

本发明公开了一种来那替尼或其药学上可接受的盐或水合物在制备预防或治疗动脉粥样硬化性疾病的药物中的应用。动脉粥样硬化性疾病是一种血管内壁慢性炎症性疾病。低密度脂蛋白和炎症性细胞持续在血管内壁受损部位累积，逐渐形成脂质条纹，进一步发展为脂质斑块，即动脉粥样硬化。来那替尼具有抑制炎症反应的效果，从而用于制备预防或治疗动脉粥样硬化性疾病的药物。

Drugs covered by this patent

Patent Metadata

Patent number
CN117427076B
Jurisdiction
CN
Classification
—
Expires
2025-09-19
Drug substance claim
No
Drug product claim
No
Assignee
Anhui Provincial Hospital First Affiliated Hospital Of Ustc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.